|
Aug 14
|
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results
|
|
Aug 13
|
ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy
|
|
Aug 11
|
ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients
|
|
Aug 5
|
ImmunityBio: Q2 Earnings Snapshot
|
|
Aug 5
|
ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code
|
|
Aug 1
|
Immunitybio (IBRX) Targets $80 Million Capital Raise for Business Operations
|
|
Jul 31
|
ImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder Cancer
|
|
Jul 25
|
ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors
|
|
Jul 25
|
ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates
|
|
Jul 23
|
ImmunityBio’s (IBRX) ANKTIVA Gets Approved by UK’s Medicines and Healthcare Regulatory Agency
|
|
Jul 2
|
ImmunityBio (IBRX) Rated Buy After FDA Approvals and Pancreatic Cancer Trial Success
|
|
Jun 5
|
Why ImmunityBio, Inc. (IBRX) Skyrocketed Today
|
|
Jun 3
|
ImmunityBio receives FDA Expanded Access authorization for Cancer BioShield
|
|
Jun 3
|
ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
|
|
Jun 2
|
ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors
|
|
May 22
|
Piper Sandler Upgrades ImmunityBio (IBRX) to Overweight, Lifts PT
|
|
May 14
|
Exploring 3 High Growth Tech Stocks In The US Market
|
|
May 14
|
Earnings Update: Here's Why Analysts Just Lifted Their ImmunityBio, Inc. (NASDAQ:IBRX) Price Target To US$13.00
|
|
Apr 21
|
ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting
|
|
Mar 13
|
ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
|